Literature DB >> 12665412

The therapeutic potential of cannabis in multiple sclerosis.

David Baker1, Gareth Pryce.   

Abstract

There has been renewed interest in the therapeutic applications of cannabis, and people, particularly those with multiple sclerosis, claim that it may offer benefit in symptom control. Cannabis exerts many of its effects because it taps into an endogenous cannabinoid system. Recent advances have begun to shine light on the biology of this system and may support some of the anecdotal medical claims. The problem with cannabis as a drug is that both the positive and negative aspects are largely the work of the same receptor. However, it may be possible to avoid these through modulation of the endogenous system. Cannabinoids provide a novel therapeutic target, not only for controlling symptoms, but also slowing disease progression through inhibition of neurodegeneration, which is the cause of accumulating irreversible disability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665412     DOI: 10.1517/13543784.12.4.561

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  7 in total

1.  Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.

Authors:  Letizia Leocani; Arturo Nuara; Elise Houdayer; Irene Schiavetti; Ubaldo Del Carro; Stefano Amadio; Laura Straffi; Paolo Rossi; Vittorio Martinelli; Carlos Vila; Maria Pia Sormani; Giancarlo Comi
Journal:  J Neurol       Date:  2015-08-20       Impact factor: 4.849

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids.

Authors:  Arkaitz Carracedo; Math J H Geelen; María Diez; Kentaro Hanada; Manuel Guzmán; Guillermo Velasco
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

4.  Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy.

Authors:  Muthu D Bhaskaran; Bret N Smith
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

Review 5.  Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies.

Authors:  Allyn C Howlett; Somnath Mukhopadhyay; Derek C Norford
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-24       Impact factor: 4.147

6.  Harm reduction--the cannabis paradox.

Authors:  Robert Melamede
Journal:  Harm Reduct J       Date:  2005-09-22

Review 7.  Dendritic Cell Regulation by Cannabinoid-Based Drugs.

Authors:  Mattias Svensson; Puran Chen; Oscar Hammarfjord
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.